Compare SCCO & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SCCO | SNY |
|---|---|---|
| Founded | 1952 | 1994 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Metal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 121.3B | 119.4B |
| IPO Year | N/A | N/A |
| Metric | SCCO | SNY |
|---|---|---|
| Price | $188.05 | $47.39 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 10 | 6 |
| Target Price | ★ $124.28 | $61.50 |
| AVG Volume (30 Days) | 1.9M | ★ 2.8M |
| Earning Date | 02-11-2026 | 01-29-2026 |
| Dividend Yield | 1.94% | ★ 3.39% |
| EPS Growth | 25.54 | ★ 105.93 |
| EPS | 4.67 | ★ 8.67 |
| Revenue | $12,334,600,000.00 | ★ $53,890,648,839.00 |
| Revenue This Year | $15.74 | $1.73 |
| Revenue Next Year | $6.81 | $6.49 |
| P/E Ratio | $39.43 | ★ $5.44 |
| Revenue Growth | ★ 12.70 | N/A |
| 52 Week Low | $72.75 | $44.62 |
| 52 Week High | $191.22 | $60.12 |
| Indicator | SCCO | SNY |
|---|---|---|
| Relative Strength Index (RSI) | 71.64 | 47.02 |
| Support Level | $174.45 | $46.10 |
| Resistance Level | $191.22 | $48.17 |
| Average True Range (ATR) | 6.86 | 0.80 |
| MACD | 1.03 | -0.02 |
| Stochastic Oscillator | 88.22 | 51.10 |
Southern Copper Corp is an integrated producer of copper and other minerals and operates the mining, smelting, and refining facilities in Peru and Mexico. Its production includes copper, molybdenum, zinc, and silver. The company operates through the following segments: Peruvian operations, Mexican open-pit operations, and Mexican underground mining operations. It generates the majority of its revenue from the sale of copper and the rest from the sale of non-copper products, such as molybdenum, silver, zinc, lead, and gold. The company's geographical segments are The Americas, Europe, and Asia.
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.